Clinical Trials Using Ganitumab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Ganitumab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Location: 16 locations
Palbociclib and Ganitumab for the Treatment of Relapsed or Refractory Ewing Sarcoma
This phase II trial studies how well palbociclib and ganitumab work in patients with Ewing sarcoma that has come back (relapsed) or does not respond to treatment (refractory). Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ganitumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving palbociclib and ganitumab may work better in treating patients with Ewing sarcoma compared to either palbociclib or ganitumab alone.
Location: 4 locations
Ganitumab, Everolimus, and Panitumumab in Treating Patients with Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of ganitumab, everolimus, and panitumumab when given together in treating patients with solid tumors that has not responded to previous treatment. Monoclonal antibodies, such as ganitumab and panitumumab, can block the ability of tumors to grow and spread by blocking protein activity which is important for tumors to grow. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ganitumab with everolimus and panitumumab may kill more tumor cells.
Location: Duke University Medical Center, Durham, North Carolina
Ganitumab and Dasatinib in Treating Patients with Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma
This phase I / II trial studies the side effects and best dose of dasatinib when given together with ganitumab and to see how well they work in treating patients with embryonal and alveolar rhabdomyosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with ganitumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving dasatinib and ganitumab may work better in treating patients with embryonal and alveolar rhabdomyosarcoma compared to standard treatment, including surgery, radiation, and / or chemotherapy.
Location: National Institutes of Health Clinical Center, Bethesda, Maryland